Postprandial Regulation of Bone Perfusion in Healthy Individuals
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age25-50
SponsorUniversity of Copenhagen
About this trial
The goal of this clinical trial is to learn whether certain natural hormones - Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-2, (GLP-2), and amylin - affect blood flow to the bones.
Eligibility criteria
Qualifiers
Age 25-50 years.
BMI between 18.5-30 kg/m2.
Normal gait.
Premenopausal (if female).
Disqualifiers
Bone disease incl. confirmed osteopenia.
Fracture within the last 6 months at the time of inclusion.
Amputation or congenital defect of extremities.
HbA1c>41.9 mmol/mol and/or diagnosed type 1 or type 2 diabetes.
Trial design
Treatments tested in this trial
- isotonic saline infusion
- Infusion of GIP(1-42)
- Infusion of GLP-2(1-33)
- Infusion of pramlintide
Treatment groups
15 Participants
are divided into 4 treatment groupsSponsors and collaborators
University of Copenhagen
Lead sponsor
Rigshospitalet, Denmark
Collaborator
Source ClinicalTrials.gov